Skip to main content
TipRanks
Go Ultimate75% OFF

ANI Pharmaceuticals (ANIP) AI Stock Analysis

373 Followers
ANIP

ANI Pharmaceuticals

(NASDAQ:ANIP)

Select Model
Rating:72Outperform
Price Target:$77.00â–²(10.02% Upside)
Action:reiterated
Date:11/06/26

Overall score is driven by strong financial performance (scaled revenue, improved margins, and solid free cash flow) and a generally positive earnings outlook with raised profitability guidance. These strengths are partially offset by weak technical momentum (price below key moving averages and negative MACD) and execution/transaction risks tied to Cortrophin conversion issues and acquisition-related dilution and leverage.

Positive Factors
Revenue and Margin ExpansionRevenue has expanded from $216M in 2021 to $1.04B TTM while margins recovered into double-digit net profitability. This combination of scale and operating improvement can support reinvestment, absorb product-level volatility, and strengthen earnings capacity over the next several quarters.
Negative Factors
Cortrophin Fulfillment BottlenecksSpecialty-pharmacy capacity constraints and slower prescriber onboarding delayed Cortrophin enrollment-to-fulfillment, causing a revenue shortfall and lower 2026 guidance. Persistent conversion friction could limit realization of demand and keep execution resource-intensive across the expanded gout opportunity.

ANI Pharmaceuticals (ANIP) vs. SPDR S&P 500 ETF (SPY)

-20%-10%0%10%20%30%ANIP-12.21%SPY+13.46%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$1.59B
Dividend Yield
―
Average Volume (3M)
416.33K
Price to Earnings (P/E)
13.5
Beta (1Y)
0.50
Revenue Growth
25.94%
EPS Growth
203.25%
Country
US
Employees
970
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

ANI Pharmaceuticals Business Overview & Revenue Model

Company Description

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel,...

How the Company Makes Money

ANI Pharmaceuticals generates revenue primarily from sales of prescription pharmaceutical products. A major component is net product revenue from its branded portfolio (where the company markets and sells its own branded medicines and records revenue...

ANI Pharmaceuticals Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:-2.32%|Next Earnings Date:Feb 26, 2027
Earnings Call SentimentPositive

The call was predominantly positive, with strong revenue, EBITDA, EPS, cash flow, generics performance, ILUVIEN growth, and raised full-year profitability guidance. ANI also highlighted the strategic and commercial potential of the Aegidus acquisition and emcetate. The main negatives were the Cortrophin revenue-conversion issues, reduced Cortrophin guidance, and expected first-year dilution from the acquisition.

Positive Updates

Strong Third-Quarter Revenue and EBITDA Growth
Total net revenue was $290.8 million in the third quarter, up 28% year over year, while adjusted EBITDA was $82.3 million, up 40% year over year. Rare disease net revenue grew 36% year over year and generics revenue increased 11% year over year.

Negative Updates

Cortrophin Revenue Fell Short of Expectations
Third-quarter Cortrophin Gel net revenue of $138.7 million was lighter than expected. ANI attributed the shortfall primarily to specialty pharmacy network capacity constraints and a longer-than-anticipated conversion of new gout cases into patients on therapy.

Company Guidance

Management expects 2026 total company net revenue of $1.085 billion to $1.125 billion, representing 25% year over year growth; Cortrophin Gel net revenue of $480 million to $500 million; ILUVIEN net revenue of $80 million to $85 million; adjusted non GAAP EBITDA of $290 million to $300 million; non GAAP earnings per share between $9.37 and $9.71 per share; adjusted gross margin in the range of 60.3% to 61%; 21.5 million and 21.8 million shares outstanding; and a full year US GAAP effective tax rate of approximately 27% to 29%, with fourth quarter revenues from the generics and Other segment expected to be relatively similar to the third quarter revenues posted this morning; the Aegidus deal is expected to close in late 26 or early 27, with trailing 12 month pro forma net leverage of approximately 2.7x, and low single digit royalty income from sales of WAKIX.

ANI Pharmaceuticals Financial Statement Overview

Summary

Strong recent fundamentals: revenue scaled materially (to ~$1.04B TTM), profitability improved to ~10.8% net margin TTM with solid ~17.4% EBIT margin, and cash generation is robust ($205M FCF TTM). Key offset is historical volatility (loss years and cash-flow swings) and debt coverage still under 1x via operating cash flow, requiring sustained execution.

Income Statement

82Very Positive

Balance Sheet

70Positive

Cash Flow

78Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.04B883.37M614.38M486.82M316.38M216.14M
Gross Profit705.65M450.64M364.17M305.30M177.60M115.53M
EBITDA270.86M207.27M63.12M106.60M25.04M3.12M
Net Income116.84M78.34M-18.52M18.78M-47.90M-42.60M
Balance Sheet
Total Assets1.57B1.44B1.28B904.42M760.09M771.60M
Cash, Cash Equivalents and Short-Term Investments436.35M285.58M151.17M221.12M48.23M100.30M
Total Debt297.68M325.19M624.09M285.67M286.52M287.37M
Total Liabilities930.55M899.65M855.17M446.82M421.55M412.86M
Stockholders Equity637.11M540.72M428.53M457.60M338.54M358.74M
Cash Flow
Free Cash Flow177.46M150.90M47.06M100.45M-47.66M-20.32M
Operating Cash Flow229.20M185.22M64.02M118.96M-31.20M3.32M
Investing Cash Flow-29.28M-34.32M-404.72M-18.51M-15.74M-105.48M
Financing Cash Flow-40.73M-9.94M264.94M67.44M-5.13M194.59M

ANI Pharmaceuticals Technical Analysis

Technical Analysis SentimentNegative
Last Price69.99

Price Trends

50DMA72.30Negative
100DMA75.31Negative
200DMA76.90Negative

Market Momentum

MACD-0.59Negative
RSI44.73Neutral
STOCH41.04Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANIP, the sentiment is Negative. The current price of 69.99 is below the 20-day moving average (MA) of 71.22, below the 50-day MA of 72.30, and below the 200-day MA of 76.90, indicating a bearish trend. The MACD of -0.59 indicates Negative momentum. The RSI at 44.73 is Neutral, neither overbought nor oversold. The STOCH value of 41.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ANIP.

ANI Pharmaceuticals Risk Analysis

ANI Pharmaceuticals disclosed 80 risk factors in its most recent earnings report. ANI Pharmaceuticals reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

3 New Risks
1.The obligations and liabilities of Egetis, some of which may be unanticipated or unknown, may be greater than we have anticipated, which may diminish the value of Egetis to us.Q3, 2026
2.We will incur substantial debt in order to satisfy our obligations in connection with the acquisition of Egetis.Q3, 2026
3.If the acquisition of Egetis is consummated, the combined company may not perform as we or the market expects, which could have an adverse effect on the price of our common stock.Q3, 2026

ANI Pharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

ANIP against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ETONETON79Outperform$1.84B35.66104.82%―100.61%―
AMPHAMPH77Outperform$1.24B12.8712.59%―3.11%-4.26%
ANIPANIP72Outperform$1.59B13.5220.00%―25.94%203.25%
COLLCOLL69Neutral$793.98M20.8512.49%―7.68%-34.31%
SUPNSUPN63Neutral$6.07B7.95-352.94%―16.44%265.06%
AMRXAMRX58Neutral$7.36B48.70131.71%―8.88%2272.07%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

0%100%200%300%ANIPSUPNAMPHCOLLAMRXETONDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ANIP and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ANIPAni Pharmaceuticals69.99-8.53-10.86%
SUPNSupernus, Inc.29.044.3917.81%
AMPHAmphastar Pharmaceuticals Inc29.103.7414.75%
COLLCollegium Pharmaceutical Inc.25.55-18.40-41.87%
AMRXAmneal Pharma21.129.6183.41%
ETONEton Pharmaceuticals63.6547.35290.49%

ANI Pharmaceuticals Corporate Events

M&A TransactionsPrivate Placements and Financing

ANI Pharmaceuticals Announces Proposed Acquisition of Egetis Therapeutics

Positive
Nov 5, 2026

On November 4, 2026, ANI Pharmaceuticals entered into a 364-day senior bridge credit facility with lenders and JPMorgan Chase Bank as administrative agent. The facility provided for borrowings of up to $676 million and was entered into in connection...

Business Operations and StrategyStock BuybackFinancial DisclosuresM&A Transactions

ANI Pharmaceuticals Reports Strong Third-Quarter Results, Expands Rare Disease Portfolio

Positive
Nov 5, 2026

On November 5, 2026, ANI Pharmaceuticals reported third-quarter revenue of $290.8 million, up 27.6% year over year, with GAAP net income of $35.1 million and adjusted non-GAAP EBITDA of $83.3 million. Cortrophin Gel revenue rose 36.1% to $138.7 milli...

Business Operations and StrategyExecutive/Board Changes

ANI Pharmaceuticals reshapes board to advance rare disease strategy

Positive
Aug 24, 2026

On August 19, 2026, ANI Pharmaceuticals appointed veteran dealmaker and strategist Henry Gosebruch to its Board of Directors, with his term running through the 2027 annual meeting of stockholders. The company highlighted his more than 30 years of bio...

Business Operations and StrategyStock BuybackFinancial Disclosures

ANI Pharmaceuticals Posts Record Q2 2026 Results

Positive
Aug 7, 2026

ANI Pharmaceuticals reported record second-quarter 2026 results on August 7, 2026, with total net revenues rising 25.9% year-over-year to $266.0 million and GAAP net income to common shareholders reaching $24.7 million. Growth was led by Purified Cor...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 06, 2026